Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
The crossover study consists of two treatment periods of 15 days duration. On Day -1 or Day 1 of Treatment Period 1, eligible participants will be randomized (1:1) to a sequence of treatments (either Lu AG06466-placebo or placebo-Lu AG06466) with 15 participants are planned per sequence. Each treatment period will be separated by a washout period of ≥7 and ≤14 days.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The participant has PTSD, diagnosed according to Diagnostic and Statistical Manual Diploma in Social Medicine-5 (DSM-5), and confirmed by the Mini International Neuropsychiatric Interview (MINI).
The participant has a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score ≥28 at screening and baseline.
The participant has alterations in arousal and reactivity, confirmed on CAPS-5.
The participant has ongoing sleep disturbances, confirmed on CAPS-5.
The participant is willing to discontinue all prohibited medications during the study and to complete a washout of psychotropic medication during the washout period.
The participant does not have any magnetic resonance imaging (MRI) contraindications.
You may not be if
The index traumatic event that led to development of PTSD took place \>15 years or \<6 months before screening.
